Citations

Showing 10 of 108162 citations.

Physiology in Perspective: Insulin—100 Years of Physiological Discovery
Sieck, Gary C.

Mayo Clinic

Physiology | April 27, 2021 | Volume: 36 | Issue: 3 | Pages: 132-133

10.1152/physiol.00007.2021 | PMID 33904787 Get It

Nivolumab with radiation therapy in a glioblastoma patient with Lynch syndrome
Sherman, Wendy , Vitaz, Todd W. , Sherman, Wendy Joyce

Mayo Clinic

BMJ Case Reports | April 27, 2021 | Volume: 14 | Issue: 4 | Pages: e241026

10.1136/bcr-2020-241026 | PMID 33906875 Get It

Lynch syndrome is an autosomal dominant disorder leading to cancer predisposition caused by mutations in mismatch repair genes. There is minimal published experience treating glioblastoma in patients with Lynch syndrome. We report a patient with Lynch syndrome who was initially diagnosed with a left occipital isocitrate dehydrogenase (IDH) wild-type glioblastoma. After resection, she was treated with chemoradiation, followed by tumour treating fields. Three years after diagnosis, recurrence was resected. After refusing cytotoxic chemotherapy, decision was made to treat with off-label nivolumab concurrently with radiation. She has been maintained on nivolumab without recurrence of her glioblastoma now over 5 years out from her initial diagnosis. This case provides the first report of glioblastoma in a patient with Lynch syndrome responding to nivolumab and concurrent radiation. In patients with Lynch syndrome and glioblastoma, immunotherapy in the form of nivolumab may be an alternative option to standard cytotoxic chemotherapy.
Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population
Fisher, Deborah A. , Karlitz, Jordan J. , Jeyakumar, Sushanth , Smith, Nathaniel , Fendrick, A. Mark , Limburg, Paul, Fendrick, A Mark , Limburg, Paul J. , Lieberman, David A.

Mayo Clinic

Journal of Medical Economics | April 27, 2021 | Volume: 24 | Issue: 1 | Pages: 654-664

10.1080/13696998.2021.1922240 | PMID 33902366 Get It

Clinical and Radiological Safety of Retained Implantable Doppler Devices Used for Free Flap Monitoring
Kreutz‐Rodrigues, Lucas , Carlsen, Brian T. , Frick, Matthew A., Bakri, Karim , Gibreel, Waleed , Mardini, Samir

Mayo Clinic

Plastic Surgery | April 27, 2021 | Volume: 30 | Issue: 1 | Pages: 20-24

10.1177/22925503211006537 | PMID 35096688 Get It

Introduction: Implantable Doppler devices are reliable adjuncts used for free flap monitoring. Occasionally, the probe/wire is not removed and remains in the soft tissues. The clinical safety of the retained probes and safety and compatibility with magnetic resonance imaging (MRI) have not been studied. We present a series of retained implantable Doppler probes examining clinic outcomes, safety and compatibility with MRI, and effect on MRI image quality. Methods: A retrospective review was conducted of patients who had an implantable Doppler device for free flap monitoring between July 2007 and August 2018. Routine post-operative imaging was reviewed for all patients to identify incidental findings of a retained probe. A subset of patients with retained implantable Doppler probes who underwent MRI was identified. Magnetic resonance images were reviewed to detect any degradation of image quality. Results: A total of 323 patients who had an implantable Doppler device placed were reviewed 18 (5.6%) patients were identified with a retained probe and were included in this study. Mean age was 49 years with mean follow-up of 34.4 months. One potential device-related complication occurred in 1 (5.6%) patient. A total of 32 MRI scans were performed in 8 patients with retained devices, including 6 patients who underwent a total of 21 MRIs of the surgical site. There were no complications related to the MRI scans, and we found no significant degradation of image quality. Conclusion: Retained implantable Doppler probes were not associated with substantial adverse clinical outcomes nor affected MRI image quality of the surgical site.
Research Highlights
Luo, Xunrong , Singh, Prince

Mayo Clinic

Transplantation | April 27, 2021 | Volume: 105 | Issue: 5 | Pages: 933-934

10.1097/tp.0000000000003760 Get It

Hemodynamic Effects of an Increased Midodrine Dosing Frequency
Macielak, Shea A. , Vollmer, Nicholas , Haddad, Natalie A., Nei, Scott D. , Vollmer, Nicholas J, Nabzdyk, Christoph G. S., Nabzdyk, Christoph S.

Mayo Clinic

Critical Care Explorations | April 27, 2021 | Volume: 3 | Issue: 4 | Pages: e0405

10.1097/cce.0000000000000405 | PMID 33912835 Get It

Objectives: In practice, midodrine has been used to reduce IV vasopressor requirements and decrease ICU length of stay. However, recent publications have failed to show clinical success when midodrine was administered every 8 hours. One possible reason for the lack of clinical efficacy at this dosing interval may be the pharmacokinetic properties of midodrine that support a more frequent dosing interval. Here, we report our institutional experience with midodrine at a dosing frequency of every 6 hours. Design: Single, quaternary academic medical center, retrospective, descriptive study. Setting: Floor and ICU patients admitted to Mayo Clinic, Rochester, from May 7, 2018, to September 30, 2020. Patients: Adult patients with an order for midodrine with a dosing frequency of “every 6 hours” or “four times daily” were eligible for inclusion. Interventions: No intervention performed. All data were abstracted retrospectively from the electronic medical record. Measurements and Main Results: Forty-four unique patients were identified that met inclusion criteria. Patients were an average of 65 years and 63.6% were male. The individual doses of midodrine ranged from 5 to 20 mg. Twenty-three patients (52.3%) were receiving IV vasopressors at the time midodrine was ordered every 6 hours. Vasopressor requirements decreased from an average of 0.10 norepinephrine equivalents 24 hours prior to the every 6-hour order to 0.05 norepinephrine equivalents 24 hours after an order for midodrine every 6 hour was placed. Conclusions: Increasing the dosing frequency of midodrine to every 6 hours may optimize its pharmacokinetic profile without compromising safety. This midodrine dosing frequency should be prospectively evaluated as a primary strategy for accelerated IV vasopressor wean.
Hydroxocobalamin in Refractory Septic Shock: A Retrospective Case Series
Sacco, Alicia , Cunningham, Cody A. , Sen, Ayan , Sacco, Alicia J, Kosiorek, Heidi

Mayo Clinic

Critical Care Explorations | April 27, 2021 | Volume: 3 | Issue: 4 | Pages: e0408

10.1097/cce.0000000000000408 | PMID 33912838 Get It

Objectives: Refractory septic shock is associated with high morbidity and mortality. Hydroxocobalamin is used to treat postoperative vasoplegia; however, data supporting its use in the setting of refractory septic shock is limited and restricted to case reports. This study evaluates the effect of hydroxocobalamin on mean arterial pressure and vasopressor requirements in a series of patients with refractory septic shock. Design: Single-center, retrospective analysis. Setting: Urban, tertiary-care ICU. Patients: Adult ICU patients with refractory septic shock treated with hydroxocobalamin between August 2018 and January 2020. Interventions: Hydroxocobalamin 5 g IV infusion. MEASUREMENTS AND MAIN RESULTS: Twenty-six patients were included for the analysis. Administration of hydroxocobalamin was associated with an increase in mean arterial pressure at 1, 6, and 24 hours postdose (+16.3, +14.3, and +16.3 mm Hg, respectively; p < 0.001). Increase in mean arterial pressure from baseline remained statistically significant when controlling for sex, age, and comorbid conditions. There was no change in the norepinephrine equivalents patients required 1 hour following hydroxocobalamin administration, but a statistically significant decrease in norepinephrine equivalent was observed at 6 and 24 hours postdose (p < 0.001). Conclusions: Hydroxocobalamin provides sustained hemodynamic benefit at 24 hours in patients with refractory septic shock.
System of Psychological Support Based on Positive Suggestions to the Critically Ill Using ICU Doulas
Karnatovskaia, Lioudmila V. , Schultz, Jason, Steele, Amanda J., Baker, Brittany A., Philbrick, Kemuel L. , Valle, Kathryn T. del , Johnson, Kimberly R. , Gajić, Ognjen, Varga, Katalin , Schultz, Jason M, Del Valle, Kathryn T, Del Valle, Kathryn T , Niven, Alexander S. , Baker, Brittany A., Gajic, Ognjen

Mayo Clinic

Critical Care Explorations | April 27, 2021 | Volume: 3 | Issue: 4 | Pages: e0403

10.1097/cce.0000000000000403 | PMID 33912833 Get It

Background: Surviving critical illness often creates a lasting psychological impact, including depression, anxiety, and post-traumatic stress. Memories of frightening and delusional experiences are the largest potentially modifiable risk factor, but currently, there is no proven intervention to improve these inciting factors. Psychological support based on positive suggestion is a psychotherapeutic approach that can be provided even to patients in altered cognitive states and is therefore a viable psychotherapy intervention throughout the ICU stay. Traditional ICU care team members have limited time and training to provide such psychological support to patients. Doulas are trained supportive companions who have been effectively used to provide patient advocacy and emotional support in other clinical settings and may address this need. Our aim was to train and implement a psychological support based on positive suggestion program for the critically ill using doulas, and measure acceptance of this intervention through stakeholder feedback. Methods: Doula training included three objectives: an introduction to ICU practice structure and policies; education about fundamental aspects of critical care conditions and procedures; and didactic and hands-on learning experiences in effective use of psychological support based on positive suggestion in the critically ill. Doulas were evaluated at the end of their training and during subsequent clinical activities using competency-based assessments as well as through survey-based questions and interviews with key stakeholders. Results: The ICU doulas performed psychological support based on positive suggestion on 43 critically ill patients in the ICU setting. Stakeholder feedback from nurses, patients, and patient families was positive. The majority (28/32) of surveyed bedside ICU nurses reported that the doulas’ involvement was helpful for both patients and nurses alike. All interviewed family members offered positive comments about the ICU doula presence and of the 40 patients who recalled the intervention 37 found it comforting. Conclusions: Our program successfully trained two doulas to work effectively in the ICU setting performing patient-centered psychological support based on positive suggestion interventions. Their training improved their skill sets and was reported as beneficial by patients, families, and critical care nursing. This training program offers a proof of concept that could be applied in other medical centers, bringing doulas more commonly into the ICU practice to help humanize the experience for patients, families, and medical teams.
Caring for Caregivers—A New Integrative Care Path for Advanced Lung Cancer Patients and Their Caregivers
McLeod, Heidi , Salinas, Manisha , Perlman, Adam I, Salinas, Manisha G, Perlman, Adam , Dabrh, Abd Moain Abu

Mayo Clinic

The Journal of Alternative and Complementary Medicine | April 27, 2021 | Volume: 27 | Issue: 5 | Pages: 377-378

10.1089/acm.2020.0396 | PMID 33902316 Get It

Plasma membrane intramembranous particle topography in 3t3 and sv3t3 cells: The effect of cytochalasin b
Scott, Robert E., Maercklein, Peter B., Furcht, Leo T., Scott, Robert E.

Mayo Clinic

Journal of Cell Science | April 27, 2021 | Volume: 23 | Issue: 1 | Pages: 173-192

10.1242/jcs.23.1.173 | PMID 561081 Get It

ABSTRACT The topography of plasma membrane intramembranous particles in contact-inhibited and transformed cells is a topic of current controversy. We have reported that particles are aggregated in 3T3 cells and that they are randomly distributed in SV3T3 cells. Other investigators have, however, proposed that these differences result from the effect of cryoprotectants and are blocked by aldehyde fixation. The experiments described in this paper re-examine PMP topography in large samples of 3T3 and SV3T3 cells prepared by a variety of preparative methods. The results confirm that 3T3 cells contain aggregated intramembranous particles and that native SV3T3 cells do not, regardless of whether cells are prepared in glycerol, sucrose, tissue culture medium or following prefixation in paraformaldehyde. Data presented in this paper also show that cytochalasin B induces dose -and time-dependent disaggregations of particles in contact-inhibited 3T3 cells. Particle disaggregation results from exposure of cells in situ for 1-3 h to 1-500 ng/ml cytochalasin B. Removal of the drug by washing with reincubation of cells in medium containing serum results in particle reaggregation within 1 to 3 h. These observations suggest that intramembranous particles in 3T3 cells are aggregated in the native state and that membrane-active drugs modulate their distribution by a mechanism possibly involving disruption of linkages between membrane components and the cytoskeleton.